Fujifilm Pharmaceuticals U.S.A., Inc.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
wral.com
·

New charter high school approved for Wake County with biotechnology focus

Holly Springs Town Council approved a life sciences-focused charter high school to be built in Holly Springs Business Park. Pine Springs Preparatory Academy, currently serving K-8, aims to bridge education and local biotech industry, preparing students for careers in southern Wake County. Construction is planned for summer 2025, pending state approval.

Evolving Surgical Precision for Cancer: CI MED Professor Leads New Virtual Organ

Dr. Claudius Conrad leads groundbreaking surgical oncology advancements using FujiFilm’s Vincent technology, integrating high-resolution imaging and AI for precise tumor removal in liver, pancreas, and bile duct surgeries. The technology creates detailed 3D models from CT scans, enhancing surgical planning and execution, while also advancing medical education through VR. This approach aims to revolutionize surgical oncology by improving safety, outcomes, and patient-centered care.
biospectrumasia.com
·

How Vietnam is Leveraging AI to Reshape Healthcare

Vietnam targets AI to boost economy, with AI contributing an estimated $79.3 billion to GDP by 2030. The National Strategy on AI aims to establish Vietnam as a leading AI nation in ASEAN and globally by 2030, including developing 10 high-profile AI brands and three national centres for big data and high-performance computing. The government collaborates with Google for AI initiatives, focusing on human resource development and startup support. AI innovations in healthcare, such as VinBrain's DrAid and AITRICS' patient deterioration prediction software, are transforming clinical practices. Challenges include the need for a comprehensive legal framework, data quality concerns, and transitioning to electronic health records.
blogs.nvidia.com
·

Japan Develops AI-Powered Drug Design, Healthcare Robotics, Digital Health Platforms

Japan is leveraging sovereign AI to enhance healthcare, addressing a projected shortage of 500,000 healthcare workers by 2024. AI tools, trained on country-specific data and local infrastructure, are deployed in drug discovery, genomic medicine, healthcare imaging, and robotics. Key technologies include NVIDIA BioNeMo for drug discovery, NVIDIA MONAI for medical imaging, NVIDIA Parabricks for genomics, and NVIDIA Holoscan for healthcare robotics. These innovations are showcased at the NVIDIA AI Summit Japan, highlighting real-time AI applications in surgery and radiology, and digital health systems for patient care.

Gut microbiome, blood glucose clinical trials most requested among Japan FFC firms

Japan's Foods with Function Claims (FFC) system allows specific health claims backed by evidence, with gut microbiome and blood glucose management studies being most common. Only 10% of FFC companies conduct clinical trials, mostly large firms. Healthy ageing and visceral fat reduction trials are also prevalent. Small and medium-sized companies typically rely on systematic reviews due to resource constraints, but standards for these reviews have recently increased.
finance.yahoo.com
·

Siemens Healthineers wins FDA approval for 3D mammography system

Siemens Healthineers received premarket approval for the 3D portion of its Mammomat B.brilliant mammography platform, featuring 50-degree wide-angle technology for faster, more accurate breast imaging. The system aims to improve detection of abnormalities and microcalcifications, with a scan time 35% faster than competitors.
openpr.com
·

Medical Image Analytics Market is Expected to Touch USD 577.02 Billion By 2032

The Medical Image Analytics Market is projected to reach USD 577.02 billion by 2032, driven by advancements in healthcare technology, AI integration, and rising demand for precise diagnostic tools. Key players include Siemens Healthineers, GE Healthcare, and IBM Watson Health, with significant growth expected in North America, Europe, and Asia Pacific.
nature.com
·

Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer

R.A.S., M.S.T., C.Y., R.N., H.S.R., M.D., A.J.C., E.S.-R., J.C.B., C.O., K.K., A.D.E., C.V., N.W., K.S.A., A.S.C., C.F., C.I., A.T., J.T., K.Y., L.H., K.G., F.M.H., T.S., A.L.A., P.B., P.N., G.L.H., W.F.S., J.P., P.P., A.D.M., D.Y., L.J.v.V., N.M.H., L.J.E. report various institutional research funding, advisory roles, consultancy, honoraria, patents, and stock ownership.
© Copyright 2024. All Rights Reserved by MedPath